AI Terminal
MEDICLINIC INTERNATIONAL PLC
Major Shareholding Notification • Apr 5, 2023
4946_mrq_2023-04-05_c7fcb3ee-2c0e-474e-9211-936e095c1789.html
Major Shareholding Notification
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4754V
Mediclinic International plc
05 April 2023
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
5 April 2023
TR-1: Standard form for notification of major holdings
- Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
The Goldman Sachs Group, Inc.
City of registered office (if applicable)
Wilmington, Delaware
Country of registered office (if applicable)
USA
4. Details of the shareholder
| Name | City of registered office | Country of registered office |
| Goldman Sachs International | London | United Kingdom |
5. Date on which the threshold was crossed or reached
31-Mar-2023
6. Date on which Issuer notified
04-Apr-2023
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 1.074447 | 3.974818 | 5.049265 | 37225409 |
| Position of previous notification (if applicable) | 1.086378 | 4.001370 | 5.087748 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| GB00B8HX8Z88 | 7921295 | 1.074447 | ||
| Sub Total 8.A | 7921295 | 1.074447% |
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
| Securities Lending | Open | 10182014 | 1.381092 | |
| Swap | 15-June-2023 | 8997334 | 1.220401 | |
| Sub Total 8.B1 | 19179348 | 2.601493% |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
| Swap | 23-May-2023 | Cash | 8680444 | 1.177418 | |
| Swap | 17-Aug-2026 | Cash | 384361 | 0.052135 | |
| Swap | 08-Mar-2033 | Cash | 259311 | 0.035173 | |
| Swap | 30-Mar-2033 | Cash | 185482 | 0.025159 | |
| Swap | 17-Aug-2026 | Cash | 132285 | 0.017943 | |
| Swap | 05-Jan-2033 | Cash | 106211 | 0.014406 | |
| Swap | 17-Aug-2026 | Cash | 92303 | 0.012520 | |
| Swap | 15-Jul-2031 | Cash | 89654 | 0.012161 | |
| Swap | 17-Aug-2026 | Cash | 45724 | 0.006202 | |
| Swap | 17-Aug-2026 | Cash | 42134 | 0.005715 | |
| Swap | 17-Aug-2026 | Cash | 36389 | 0.004936 | |
| Swap | 17-Aug-2026 | Cash | 19183 | 0.002602 | |
| Swap | 17-Aug-2026 | Cash | 12608 | 0.001710 | |
| Swap | 17-Aug-2026 | Cash | 12160 | 0.001649 | |
| Swap | 20-Oct-2032 | Cash | 8893 | 0.001206 | |
| Swap | 17-Aug-2026 | Cash | 5939 | 0.000806 | |
| Swap | 17-Aug-2026 | Cash | 3974 | 0.000539 | |
| Swap | 17-Aug-2026 | Cash | 3606 | 0.000489 | |
| Swap | 28-Jul-2032 | Cash | 1915 | 0.000260 | |
| Swap | 11-Oct-2023 | Cash | 1381 | 0.000187 | |
| Swap | 17-Aug-2026 | Cash | 756 | 0.000102 | |
| Swap | 30-May-2023 | Cash | 37 | 0.000005 | |
| Swap | 09-May-2023 | Cash | 16 | 0.000002 | |
| Sub Total 8.B2 | 10124766 | 1.373325% |
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
| The Goldman Sachs Group, Inc. (Chain 1) | ||||
| The Goldman Sachs Group, Inc. (Chain 1) | Goldman Sachs (UK) L.L.C. | 1.063875 | 3.974616 | 5.038491% |
| The Goldman Sachs Group, Inc. (Chain 1) | Goldman Sachs Group UK Limited | 1.063875 | 3.974616 | 5.038491% |
| The Goldman Sachs Group, Inc. (Chain 1) | Goldman Sachs International | 1.063875 | 3.974616 | 5.038491% |
| The Goldman Sachs Group, Inc. (Chain 2) | ||||
| The Goldman Sachs Group, Inc. (Chain 2) | GSAM Holdings LLC | |||
| The Goldman Sachs Group, Inc. (Chain 2) | Goldman Sachs Asset Management, L.P. | |||
| The Goldman Sachs Group, Inc. (Chain 3) | ||||
| The Goldman Sachs Group, Inc. (Chain 3) | Goldman Sachs Bank USA | |||
| The Goldman Sachs Group, Inc. (Chain 3) | Goldman Sachs Bank Europe SE | |||
| The Goldman Sachs Group, Inc. (Chain 4) | ||||
| The Goldman Sachs Group, Inc. (Chain 4) | Goldman Sachs & Co. LLC |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Please note, the total amount of voting rights have been rounded to 6 decimal places therefore there is a possibility of a rounding error.
General email contact:
12. Date of Completion
04-Apr-2023
13. Place Of Completion
Warsaw
ABOUT MEDICLINIC INTERNATIONAL PLC
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 31 December 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and five day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 750 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUVOKROSUSRRR